Structural Heart最新文献

{"title":"Editorial: Real World Transcatheter Edge to Edge Repair Eligibility in HF Patients: Finding the Opportunity","authors":"Anita W. Asgar MD, MSc, Theofilos Panagiotidis MD","doi":"10.1016/j.shj.2023.100274","DOIUrl":"10.1016/j.shj.2023.100274","url":null,"abstract":"","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 2","pages":"Article 100274"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623002245/pdfft?md5=050dd7bf34c29ef5ecd55d57232718e4&pid=1-s2.0-S2474870623002245-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139538116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Simple Technique for Deploying the SENTINEL Cerebral Protection System in Bovine Aortic Arch Anatomy","authors":"Ajoe John Kattoor MD,&nbsp;Christopher Manion MD,&nbsp;Vijay Iyer MD, PhD","doi":"10.1016/j.shj.2023.100228","DOIUrl":"10.1016/j.shj.2023.100228","url":null,"abstract":"<div><p>The SENTINEL Cerebral Protection System is one of the most commonly used devices for embolic protection during transcatheter aortic valve replacement. However, successful deployment of the SENTINEL device is often challenging in patients with a bovine aortic arch anatomy using the standard technique and requires extensive manipulation in the aortic arch increasing the risk of stroke. We describe a novel and simple technique of 2-filter deployment of SENTINEL device in patients with bovine arch anatomy. In this technique, after the deployment of the proximal filter, the device is hyperflexed on itself facing the lateral aspect of the ascending aorta instead of facing the descending aorta, with its tip pointing toward the common origin of the left common carotid artery (LCCA) and brachiocephalic trunk. The guidewire is then advanced to the LCCA. Since the guidewire can pass either anterior or posterior to the device shaft, the device needs to be untwisted either by clockwise or counterclockwise motion, before pulling the device shaft back to engage the LCCA, after which the distal filter can be deployed. Computed tomography scans obtained for planning transcatheter aortic valve replacement should be reviewed for the presence of bovine aortic arch anatomy so that this technique can be deployed directly, thereby reducing manipulations in the aortic arch, saving time, and not requiring additional equipment.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 2","pages":"Article 100228"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001227/pdfft?md5=7759bd00e6827626f09d5c2d4a17dfd0&pid=1-s2.0-S2474870623001227-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135809361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and Outcomes of Patients Receiving a Second Rescue Valve During Transcatheter Aortic Valve Implantation","authors":"Henrik Bjursten MD, PhD ,&nbsp;Sasha Koul MD, PhD ,&nbsp;Pétur Pétursson MD, PhD ,&nbsp;Jacob Odenstedt MD, PhD ,&nbsp;Henrik Hagström MD ,&nbsp;Jenny Backes MD ,&nbsp;Niels Erik Nielsen MD, PhD ,&nbsp;Andreas Rück MD, PhD ,&nbsp;Jan Johansson MD ,&nbsp;Stefan James MD, PhD ,&nbsp;Magnus Settergren MD, PhD ,&nbsp;Matthias Götberg MD, PhD ,&nbsp;Troels Yndigen MD","doi":"10.1016/j.shj.2023.100231","DOIUrl":"10.1016/j.shj.2023.100231","url":null,"abstract":"<div><h3>Background</h3><p>Transcatheter aortic valve implantation (TAVI) has become a safe procedure. However, complications occur, including uncommon complications such as valve malposition, which requires the implantation of an additional rescue valve (rescue-AV). The aim was to study the occurrence and outcomes of rescue-AV in a nationwide registry.</p></div><div><h3>Methods</h3><p>The Swedish national TAVI registry was used as the primary data source, where all 6706 TAVI procedures from 2016 to 2021 were retrieved. Nontransfemoral access and planned valve-in-valve were excluded. In total, 79 patients were identified as having had a rescue-AV, and additional detailed data were collected for these patients. This dataset was analyzed for any characteristics that could predispose patients to a rescue-AV. The outcome of patients receiving rescue-AV also was studied.</p></div><div><h3>Results</h3><p>Of the 5948 patients in the study, 1.3% had a rescue-AV. There were few differences between patients receiving 1 valve and rescue-AV patients. For patients receiving a rescue-AV, the 30-day mortality was 15.2% compared to 1.6% in the control group. A poor outcome after rescue-AV was often associated with a second complication; for example, stroke, need for emergency surgery, or heart failure. Among the patients with rescue-AV who survived at least 30 days, landmark analyses showed similar survival rates compared to the control group.</p></div><div><h3>Conclusions</h3><p>Among TAVI patients in a nationwide register, rescue-AV occurred in 1.3% of patients. The 30-day mortality in patients receiving rescue-AV was high, but long-term outcome among 30-day survivors was similar to the control group.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 2","pages":"Article 100231"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001252/pdfft?md5=d8e7317bcc2e227b6226a3cbf035db7d&pid=1-s2.0-S2474870623001252-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135765403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eligibility and Potential Benefit of Transcatheter Edge-to-Edge Repair in a Contemporary Cohort With Heart Failure: Evidence From a Large Integrated Health Care Delivery System","authors":"Andrew P. Ambrosy MD ,&nbsp;Jingrong Yang MA ,&nbsp;Andrew S. Tai MD ,&nbsp;Sadia J. Dimbil MD ,&nbsp;Elisha A. Garcia BS ,&nbsp;Sue Hee Sung MPH ,&nbsp;Ankeet S. Bhatt MD, MBA ,&nbsp;Matthew D. Solomon MD, PhD ,&nbsp;Ivy A. Ku MD, MAS ,&nbsp;Jacob M. Mishell MD ,&nbsp;Edward J. McNulty MD ,&nbsp;Jonathan G. Zaroff MD ,&nbsp;Andrew N. Rassi MD ,&nbsp;Jeremy Kong MD ,&nbsp;Alan S. Go MD","doi":"10.1016/j.shj.2023.100237","DOIUrl":"10.1016/j.shj.2023.100237","url":null,"abstract":"<div><h3>Background</h3><p>The eligibility and potential benefit of transcatheter edge-to-edge repair (TEER) in addition to guideline-directed medical therapy to treat moderate-severe or severe secondary mitral regurgitation (MR) has not been reported in a contemporary heart failure (HF) population.</p></div><div><h3>Methods</h3><p>Eligibility for TEER based on Food and Drug Administration (FDA) labeling: (1) HF symptoms, (2) moderate-severe or severe MR, (3) left ventricular ejection fraction (LVEF) 20% to 50%, (4) left ventricular end-systolic dimension 7.0 cm, and (5) receiving GDMT (blocker + angiotensin-converting enzyme inhibitor/angiotensin receptor blocker). The proportion (%) of patients eligible for TEER. The hypothetical number needed to treat to prevent or postpone adverse outcomes was estimated using relative risk reductions from published hazard ratios in the registration trial and the observed event rates.</p></div><div><h3>Results</h3><p>We identified 50,841 adults with HF and known LVEF. After applying FDA criteria, 2461 patients (4.8%) were considered eligible for transcatheter mitral valve replacement (FDA+), with the vast majority of patients excluded (FDA-) based on a lack of clinically significant MR (N = 47,279). FDA+ patients had higher natriuretic peptide levels and were more likely to have a prior HF hospitalization compared to FDA- patients. Although FDA+ patients had a more dilated left ventricle and lower LVEF, median (25th-75th) left ventricular end-systolic dimension (cm) was low at 4.4 (3.7-5.1) and only 30.8% had severely reduced LVEF. FDA+ patients were at higher risk of HF-related morbidity and mortality. The estimated number needed to treat to potentially prevent or postpone all-cause hospitalization was 4.4, 8.8 for HF hospitalization, and 5.3 for all-cause death at 24 months in FDA+ patients.</p></div><div><h3>Conclusions</h3><p>There is a low prevalence of TEER eligibility based on FDA criteria primarily due to absence of moderate-severe or severe MR. FDA+ patients are a high acuity population and may potentially derive a robust clinical benefit from TEER based on pivotal studies. Additional research is necessary to validate the scope of eligibility and comparative effectiveness of TEER in real-world populations.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 2","pages":"Article 100237"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001318/pdfft?md5=dcd42176220bdea1430d127bbd5ce43f&pid=1-s2.0-S2474870623001318-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Limitation of Limitations","authors":"Anthony DeMaria MD","doi":"10.1016/j.shj.2024.100283","DOIUrl":"https://doi.org/10.1016/j.shj.2024.100283","url":null,"abstract":"","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 2","pages":"Article 100283"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870624000046/pdfft?md5=2f380127a27ec03a338c46d9fd7f79d5&pid=1-s2.0-S2474870624000046-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139999971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leaflet Mechanical Stress in Different Designs and Generations of Transcatheter Aortic Valves: An in Vitro Study","authors":"Viktória Stanová Dipl-Ing, MSc, PhD ,&nbsp;Régis Rieu Dipl-Ing, PhD ,&nbsp;Lionel Thollon PhD ,&nbsp;Erwan Salaun MD, PhD ,&nbsp;Josep Rodés-Cabau MD ,&nbsp;Nancy Côté PhD ,&nbsp;Diego Mantovani Dipl-Ing, PhD ,&nbsp;Philippe Pibarot DVM, PhD","doi":"10.1016/j.shj.2023.100262","DOIUrl":"10.1016/j.shj.2023.100262","url":null,"abstract":"<div><h3>Background</h3><p>It is unknown whether bioprostheses used for transcatheter aortic valve implantation will have similar long-term durability as those used for surgical aortic valve replacement. Repetitive mechanical stress applied to the valve leaflets, particularly during diastole, is the main determinant of structural valve deterioration. Leaflet mechanical stress cannot be measured in vivo. The objective of this in vitro/in silico study was thus to compare the magnitude and regional distribution of leaflet mechanical stress in old vs new generations of self-expanding (SE) vs balloon expandable (BE) transcatheter heart valves (THVs).</p></div><div><h3>Methods</h3><p>A double activation simulator was used for in vitro testing of two generations of SE THV (Medtronic CoreValve 26 mm and EVOLUT PRO 26 mm) and two generations of BE THV (Edwards SAPIEN 23 mm vs SAPIEN-3 23 mm). These THVs were implanted within a 21-mm aortic annulus. A noncontact system based on stereophotogammetry and digital image correlation with high spatial and temporal resolution (2000 img/sec) was used to visualize the valve leaflet motion and perform the three-dimensional analysis. A finite element model of the valve was developed, and the leaflet deformation obtained from the digital image correlation analysis was applied to the finite element model to calculate local leaflet mechanical stress during diastole.</p></div><div><h3>Results</h3><p>The maximum von Mises leaflet stress was higher in early vs new THV generation (<em>p</em> &lt; 0.05) and in BE vs SE THV (<em>p</em> &lt; 0.05): early generation BE: 2.48 vs SE: 1.40 MPa; new generation BE: 1.68 vs SE: 1.07 MPa. For both types of THV, the highest values of leaflet stress were primarily observed in the upper leaflet edge near the commissures and to a lesser extent in the mid-portion of the leaflet body, which is the area where structural leaflet deterioration most often occurs in vivo.</p></div><div><h3>Conclusions</h3><p>The results of this in vitro/in silico study suggest that: i) Newer generations of THVs have ∼30% lower leaflet mechanical stress than the early generations; ii) For a given generation, SE THVs have lower leaflet mechanical stress than BE THVs. Further studies are needed to determine if these differences between new vs early THV generations and between SE vs BE THVs will translate into significant differences in long-term valve durability in vivo.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 2","pages":"Article 100262"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001987/pdfft?md5=87b82c12387f302694e45cd357df1f66&pid=1-s2.0-S2474870623001987-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138993879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Femoral Arterial Calcification and Plug- vs. Suture-Based Closure Device Strategies Post-Transcatheter Aortic Valve Implantation: Insights From CHOICE-CLOSURE","authors":"Sean Fitzgerald MD ,&nbsp;Oliver Dumpies MD ,&nbsp;Masafumi Shibata MD ,&nbsp;Philipp Hartung MD ,&nbsp;Danilo Obradovic MD ,&nbsp;Peter Boekstegers MD ,&nbsp;Marc Vorpahl MD ,&nbsp;Johannes Rotta detto Loria MD ,&nbsp;Philipp Kiefer MD ,&nbsp;Steffen Desch MD ,&nbsp;Holger Thiele MD ,&nbsp;Mohamed Abdel-Wahab MD","doi":"10.1016/j.shj.2023.100236","DOIUrl":"10.1016/j.shj.2023.100236","url":null,"abstract":"<div><h3>Background</h3><p>The location and severity of vascular calcification may influence closure device success in transfemoral transcatheter aortic valve implantation. The aim of this study was to analyze effects of vascular access-site calcification on vascular and bleeding outcomes post-transcatheter aortic valve implantation.</p></div><div><h3>Methods</h3><p>The Randomized Comparison of CatHeter-based Strategies fOr Interventional ACcess SitE CLOSURE during Transfemoral Transcatheter Aortic Valve Implantation (CHOICE-CLOSURE) trial assigned 516 patients to access site closure using a pure plug-based technique (MANTA, Teleflex) or a primary suture-based technique (ProGlide, Abbott Vascular). The principal finding of the overall study was that access-site or access-related complications were more common after the plug-based strategy compared to percutaneous closure with a suture-based strategy. In this predefined subgroup analysis, the overall cohort was split into patients with and without anterior calcification at the access site and divided by degree of calcification severity using the classification system developed in the MANTA vs. suture-based vascular closure after transcatHeter aortic valve replacement (MASH) trial. Differences in bleeding and vascular complications were compared. The primary endpoint consisted of access-site- or access-related major and minor vascular complications.</p></div><div><h3>Results</h3><p>There were more access-site-related major and minor vascular complications for patients with anterior wall vascular calcification and MASH severe calcification. No significant interaction with choice of closure technique in terms of access-site-related major and minor vascular complications was observed (odds ratio 1.70, 95% CI 0.77-3.78, <em>p</em> = 0.19 for the primary endpoint in plug- vs. suture-based strategy in patients with anterior calcification, odds ratio 1.78, 95% CI 0.56-5.65, <em>p</em> = 0.33 for primary endpoint in plug- vs. suture-based strategy with MASH severe calcification, p_int = 0.97 for anterior calcification, p_int = 0.95 for MASH severe calcification).</p></div><div><h3>Conclusions</h3><p>The total number of vascular complications was found to be greater in the presence of anterior and MASH severe calcification. Overall, the presence of anterior or severe calcification does not significantly modify the efficacy of the suture-based strategy compared to the plug-based strategy.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 2","pages":"Article 100236"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623001306/pdfft?md5=07f70fcdd88d12d618e4ebc7bcef28de&pid=1-s2.0-S2474870623001306-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138612561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Structural and Functional Remodeling After Transcatheter Mitral Valve in Valve Implantation: Early Changes and Prognostic Significance","authors":"Gloria Ayuba DO ,&nbsp;Zhiying Meng MS ,&nbsp;Abigail S. Baldridge PhD ,&nbsp;Ansh Goyal MS ,&nbsp;Blair Tilkens MD ,&nbsp;Rishi Shrivastav MD ,&nbsp;Taimur Safder MD ,&nbsp;Chris S. Malaisrie MD ,&nbsp;James Flaherty MD ,&nbsp;Patrick M. McCarthy MD ,&nbsp;James D. Thomas MD ,&nbsp;Charles Davidson MD ,&nbsp;Jyothy Puthumana MD ,&nbsp;Akhil Narang MD","doi":"10.1016/j.shj.2023.100264","DOIUrl":"10.1016/j.shj.2023.100264","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Transcatheter mitral valve-in-valve (MViV) replacement has emerged as an alternative to redo mitral valve (MV) surgery for the management of failed bioprosthetic MVs. The degree of cardiac remodeling assessed by echocardiography has been shown to have prognostic implications in degenerative mitral regurgitation patients undergoing MV surgery. The impact of transcatheter MViV in patients with degenerative bioprosthetic MV failure on cardiac remodeling and its associated prognosis remains undescribed.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;p&gt;The aim of this study is to describe the early anatomic and functional changes of the left-sided chambers and right ventricle by echocardiography posttranscatheter MViV intervention and their impact on mortality outcomes. Additionally, we sought to analyze the outcome of heart failure in bioprosthetic MV failure patients undergoing transcatheter MViV replacement.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;We analyzed consecutive patients undergoing MViV intervention for symptomatic bioprosthetic MV failure. Echocardiograms before intervention and within 100 days postintervention were analyzed. A chart review was performed to obtain baseline characteristics, follow-up visits, 30-day heart failure and 1-year all-cause mortality outcomes.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;A total of 62 patients (mean age 69 ± 13 years, 61% male) were included in the study. Most patients were undergoing MViV intervention for prosthetic mitral stenosis n = 48 (77.4%) and the rest for mitral regurgitation or mixed disease. Compared with baseline, significant reductions were observed in median left atrial volume (LAV; 103 [81–129] ml vs. 95.2 [74.5–117.5] ml, &lt;em&gt;p&lt;/em&gt; &lt; 0.01) and mean (SD) left atrial conduit strain (9.1% ± 5.2% vs. 10.8% ± 4.8%, &lt;em&gt;p&lt;/em&gt; = 0.039) within 100 days postintervention. Early reduction in right ventricular free wall global longitudinal strain and fractional area change also occurred postintervention. No significant change in left ventricular chamber dimensions or ejection fraction was observed. During the 1-year follow up period, 5 (8%) patients died. While baseline LAV was not associated with 1-year all-cause mortality (OR 0.98 CI 0.95–1.01; &lt;em&gt;p&lt;/em&gt; = 0.27), a change in LAV in the follow up period was associated with all-cause mortality at 1 year (OR 1.06 CI 1.01–1.12; &lt;em&gt;p&lt;/em&gt; = 0.023). At 30 days postintervention, 65% of patients had an improvement in their New York Heart Association functional class.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;In this retrospective study of patients undergoing transcatheter MViV intervention for failed bioprosthetic MVs, early reverse remodeling of the left atrium occurs within 100 days postintervention and reduction in LAV is associated with reduced all-cause mortality at 1 year. In addition, there is significant improvement in heart failure symptoms at 30 days following intervention but further investigation into the longitudinal remodeling changes and ","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 2","pages":"Article 100264"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870623002002/pdfft?md5=662400a67045ee3bc8ca7560f28f3c97&pid=1-s2.0-S2474870623002002-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139193798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and Outcomes of Patients Ineligible for Tricuspid Transcatheter Edge-to-Edge Repair","authors":"Taha Hatab MD ,&nbsp;Rody G. Bou Chaaya MD ,&nbsp;Sahar Samimi MD ,&nbsp;Fatima Qamar MD ,&nbsp;Nadeen Faza MD ,&nbsp;Stephen H. Little MD ,&nbsp;Michael J. Reardon MD ,&nbsp;Neal S. Kleiman MD ,&nbsp;William A. Zoghbi MD ,&nbsp;Ashrith Guha MD ,&nbsp;Syed Zaid MD ,&nbsp;Sachin S. Goel MD","doi":"10.1016/j.shj.2023.100235","DOIUrl":"https://doi.org/10.1016/j.shj.2023.100235","url":null,"abstract":"","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 2","pages":"Article 100235"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S247487062300129X/pdfft?md5=1f976bc66b1481839ebedca965ef8d9a&pid=1-s2.0-S247487062300129X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139999480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aims & Scope","authors":"","doi":"10.1016/S2474-8706(24)00016-2","DOIUrl":"https://doi.org/10.1016/S2474-8706(24)00016-2","url":null,"abstract":"","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"8 2","pages":"Article 100290"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2474870624000162/pdfft?md5=e0de5f4c9427e81ac6b66e4b84e9637b&pid=1-s2.0-S2474870624000162-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139999970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}